Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Dermata Therapeutics has successfully completed its initial public offering, closing on the sale of 2,571,428 shares of common stock and accompanying warrants at $7.00 per share, raising approximately $18 million. The company intends to utilize the proceeds to further develop its clinical products, including DMT310 and DMT410, targeting conditions such as rosacea, psoriasis, and aesthetic indications. The offering included an option for underwriters to purchase additional shares, which has been partially exercised. Shares began trading on the Nasdaq under the symbols DRMA and DRMAW.